Smith & Nephew Holders Oppose Executive Pay Deal
April 14 2016 - 3:30PM
Dow Jones News
LONDON—A majority of Smith & Nephew PLC's shareholders voted
down the company's pay decisions for its top executives, over a
rift on how it awarded bonuses.
The medical-device maker said 53% of investors opposed its
remuneration report for 2015, though the nonbinding vote won't
affect last year's management pay packages. That vote came hours
after a majority of investors in oil giant BP PLC voted down its
executive-pay policy.
The rebellion centered on the remuneration committee's decision
to award a combined £ 2.1 million ($3 million) in bonus payments to
Smith & Nephew's top 60 executives even though the company's
total shareholder return lagged behind the median of its peer
group. That decision overrode the company's own pay policy, which
stipulated that management would receive a bonus only if total
shareholder return was at or above that benchmark.
Joseph Papa, chairman of the remuneration committee, said in the
company's annual report that the decision was "not taken lightly,"
and reflected volatility within the peer group. Of the 18 companies
in Smith & Nephew's peer group at the start of the period,
three were acquired, resulting in share-price spikes for those
companies. Danaher Corp. bought Nobel Biocare Holding AG, Medtronic
Inc. (now Medtronic PLC) bought Covidien PLC and Smith & Nephew
itself bought ArthroCare PLC.
Mr. Papa sais that Smith & Nephew's total shareholder return
over the previous three years, at 80%, was "significantly ahead" of
broad market indexes, both in the U.K. and U.S. "Ultimately, we
have made a decision that we believe to be in the best interests of
shareholders, reflecting the corporate performance delivered, while
continuing to engage and incentivize the company's senior
management over the longer term," he said.
A spokesman for the company said the board consulted with
shareholders representing around 20% of the company's equity before
making the decision. None of those investors supported changing the
peer group, and around half said the committee should be able to
use its discretion on pay.
The spokesman acknowledged that a "significant number" of
shareholders were opposed to the principle of exercising discretion
on pay. Institutional Shareholder Services, an influential investor
adviser, recommended to clients that they vote against the pay
decision "given the obvious concern with awards paying out when
targets have not been met."
The company said the committee was now undertaking a "thorough
review" of remuneration arrangements for 2016, ahead of putting a
new policy to a shareholder vote in 2017.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
April 14, 2016 15:15 ET (19:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024